ArticleBMC cancer2026
Association of sarcopenia with pathologic complete response in esophageal squamous cell carcinoma patients undergoing neoadjuvant immunochemotherapy.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSarcopenia can affect the efficacy of neoadjuvant chemotherapy or chemoradiotherapy for esophageal squamous cell carcinoma. However, the extent of this relationship in patients treated with neoadjuvant immunochemotherapy has not been fully explored.
methodsA retrospective cohort study was conducted on 150 patients with locally advanced esophageal squamous cell carcinoma who underwent two or three cycles of neoadjuvant immunochemotherapy, followed by surgical resection. We analyzed the correlation between clinicopathological factors—including sarcopenia before neoadjuvant immunochemotherapy and excessive muscle loss during neoadjuvant therapy—and the occurrence of pathologic complete response.
resultsBefore neoadjuvant immunochemotherapy, 55.3% of patients were classified as having sarcopenia, and this proportion increased to 68.0% after neoadjuvant immunochemotherapy. A total of 20.7% of patients (31/150) achieved pathologic complete response. Multivariate logistic regression analyses revealed that sarcopenia before neoadjuvant immunochemotherapy (odds ratio = 2.696, P = 0.023) and excessive muscle loss during treatment (odds ratio = 3.999, P = 0.038) were independent predictors of failure to achieve pathologic complete response after neoadjuvant immunochemotherapy.
conclusionsThe study identified sarcopenia before neoadjuvant immunochemotherapy and excessive muscle loss during treatment as important adverse factors associated with a lower likelihood of achieving pathologic complete response in esophageal squamous cell carcinoma patients undergoing neoadjuvant immunochemotherapy. Consequently, our findings underscore the crucial role of preoperative sarcopenia in influencing treatment outcomes of neoadjuvant immunochemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.